SEC Form 4 · accession 0001209191-17-027725
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saeed Motahari
Officer — President & CEO · Director
Period of report
Apr 17, 2017
Accepted (ET)
Apr 20, 2017 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.57 | Apr 17, 2017 | A | 325,000 | A | — | Apr 16, 2027 | Common Stock | 325,000 | 325,000 | D |
| Restricted Stock UnitsF2,F3 | — | Apr 17, 2017 | A | 33,000 | A | — | — | Common Stock | 33,000 | 33,000 | D |
Explanation of responses
- F1The option vests in 48 equal monthly installments and will be fully vested and exercisable on April 17, 2021.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on April 17, 2017. The RSUs vest in 3 equal annual installments beginning on April 17, 2018 and will be fully vested on April 17, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.